Threshold Pharmaceuticals, Inc Patent applications |
Patent application number | Title | Published |
20160045522 | Treatment of Cancer - This invention provides medicines and technology for use in treating cancer. The approach is to administer a hypoxia activated prodrug, followed by administration of another chemotherapeutic agent that is not a hypoxia activated prodrug. The median survival in pancreatic cancer patients can be extended by several months using such medicines and technology. This invention also provides methodology to assist the clinician in identifying subjects who will benefit most from the therapy. Drug combinations are provided to help the clinician manage side effects that may occur in the course of treatment. | 02-18-2016 |
20150258125 | TREATMENT OF CANCER USING HYPOXIA ACTIVATED PRODRUGS - Cancer can be treated by administration of a hypoxia-activated prodrug, such as TH-302, alone or in combination with other anticancer agents and/or radiation therapy. In combination therapy, the hypoxia-activated prodrug and another anticancer agent or radiation therapy may be administered within the same 24-hour period, and administration of the hypoxia-activated prodrug may be completed prior to beginning administration of the other anticancer agent or radiation therapy. | 09-17-2015 |
20140171389 | METHODS FOR TREATING CANCER - Administration of TH-302 or another hypoxia activated prodrug in combination with a pharmacological agent that down-regulates or inhibits homology directed repair (HDR) is useful for treating cancer. | 06-19-2014 |
20140170240 | Phosphoramidate Alkylator Prodrugs - Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents. | 06-19-2014 |
20140072624 | UNIT DOSE FORM FOR ORAL ADMINISTRATION - Formulations and unit dose forms of TH-302 and other hypoxia activated prodrugs suitable for oral administration are useful for treating cancer. | 03-13-2014 |
20130303778 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS - Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents. | 11-14-2013 |
20130296273 | TREATMENT OF BLOOD CANCER - Hypoxia activated prodrugs, such as, e.g., TH-281, TH-302, and TH-308, are useful for the treatment of various blood cancers, such as acute leukemias, chronic leukemias, MDS, MF, and multiple myeloma. | 11-07-2013 |
20130045944 | Anti-Cancer Therapies - Methods for the treatment of cancer are described. In particular, methods for treatment of cancer comprising administration of glufosfamide alone or in combination with another anticancer agent are disclosed. | 02-21-2013 |
20110251159 | Phosphoramidate Alkylator Prodrugs - Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents. | 10-13-2011 |
20110182909 | Glufosfamide combination therapy - Glufosfamide administered in combination with other chemotherapeutic agents is useful in cancer treatment. | 07-28-2011 |
20100183742 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS FOR THE TREATMENT OF CANCER - Compositions containing, and, methods administering, TH302, are useful in treatment of cancer and other hyper-proliferative diseases. | 07-22-2010 |
20100104549 | GLUFOSFAMIDE COMBINATION THERAPY - The co-administration of glufosfamide and a glucose lowering drug other than insulin is efficacious in cancer treatment. | 04-29-2010 |
20090042820 | Tubulin Binding Anti Cancer Agents And Prodrugs Thereof - Novel tubulin binding compounds and hypoxia activated prodrugs of novel and known tubulin binding compounds useful for treating cancer and other hyperproliferative diseases are disclosed. | 02-12-2009 |
20080214576 | Topoisomerase Inhibitors and Prodrugs - Compositions and methods for treating cancer and other hyperproliferatice disease conditions with topoisomerase inhibitors and their prodrugs are disclosed. | 09-04-2008 |